Một phương pháp dựa trên lý thuyết thông tin để đánh giá dấu ấn thay thế với các điểm kết thúc thời gian thất bại

Alonso A, Molenberghs G (2007) Surrogate marker evaluation from an information theory perspective. Biometrics 63: 180–186 Alonso A, Molenberghs G (2008) Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective. Stat Methods Med Res 17: 497–504 Alonso A, Molenberghs G, Burzykowski T, Renard D, Geys H, Shkedy Z, Tibaldi F, Cortiñas J, Buyse M (2004) Prentice’s approach and the meta-analytic paradigm: a reflection on the role of statistics in the evaluation of surrogate endpoints. Biometrics 60: 724–728 Alonso A, Molenberghs G, Geys H, Buyse M (2005) A unifying approach for surrogate marker validation based on Prentice’s criteria. Stat Med 25: 205–211 Alonso A, Geys H, Molenberghs G (2006) A unifying approach for surrogate marker validation based on Prentices criteria. Stat Med 25: 205–221 Boltzmannn L (1877) Über die Beziehung zwischen dem zweiten Hauptsatze der mechanischen Wärmetheorie und der Wahrscheinlichkeitsrechnung respecktive den Sätzen über das Wärmegleichgewicht (On the relationship between the second law of the mechanical theory of heat and the probability calculus). Wiener Berichte 2: 373–435 Burzykowski T, Molenberghs G, Buyse M, Renard D, Geys H (2001) Validation of surrogate endpoints in multiple randomized clinical trials with failure-time endpoints. Appl Stat 50: 405–422 Burzykowski T, Molenberghs G, Buyse M (2005) The Evaluation of surrogate endpoints. Springer, New York Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H (2000) The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 1: 49–67 Cardiac Arrhythmia Suppression Trial (CAST) Investigators: (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infraction. N Engl J Med 321: 406–412 Clayton DG (1978) A model for association in bivariate life tables and its application in epidemiological studies of familial tendency in chronic disease incidence. Biometrika 65: 41–151 Cover T, Tomas J (1991) Elements of information theory. Wiley, New York Cox DR (1972) Regression models and life tables (with discussion). J R Stat Soc B 34: 187–220 Cox DR (1975) Partial likelihood. Biometrika 62: 269–276 Cox DR, Oakes D (1984) Analysis of survival data. Chapman and Hall, London Daniels MJ, Hughes MD (1997) Meta-analysis for the evaluation of potential surrogate markers. Stat Med 16: 1515–1527 DeGruttola V, Fleming TR, Lin DY, Coombs R (1997) Validating surrogate markers—are we being naive?. J Infect Dis 175: 237–246 Duchateau L, Janssen P (2007) The Frailty Model. Springer, New York Dunn N, Mann RD (1999) Prescription-event and other forms of epidemiological monitoring of side-effects in the UK. Clin Exp Allergy 29: 217–239 Fisher R (1925) Theory of statistical estimation. Proc Camb Philos Soc 22: 700–725 Fleming TR, DeMets DL (1996) Surrogate endpoints in clinical trials: are we being misled?. Ann Intern Med 125: 605–613 Freedman LS, Graubard BI, Schatzkin A (1992) Statistical validation of intermediate endpoints for chronic diseases. Stat Med 11: 167–178 Hartley R (1928) Transmission of information. Bell Syst Tech J 7: 535–563 Henderson R, Diggle P, Dobson A (2000) Joint modelling of longitudinal measurements and event time data. Biostatistics 1: 465–480 Hougaard P (2000) Analysis of multivariate survival data. Springer, New York Kalbfleisch J, Prentice RL (1980) The statistical analysis of failure time data. Wiley, New York Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481 Kent J (1983) Information gain and a general measure of correlation. Biometrika 70: 163–173 Kent J (1986) The underlying structure of nonnested hypothesis tests. Biometrika 73: 333–344 Kent J, O’Quigley J (1988) Measure of dependence for censored survival data. Biometrika 75: 525–534 Kullback S, Leibler R (1951) On information and sufficiency. Ann Math Stat 22: 79–86 Lagakos SW, Hoth DF (1992) Surrogate markers in AIDS: where are we? Where are we going?. Ann Intern Med 116: 599–601 Lesko LJ, Atkinson AJ (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41: 347–366 Molenberghs G, Kenward MG (2007) Missing data in clinical studies. Wiley, Chichester Molenberghs G, Burzykowski T, Alonso A, Assam P, Tilahun A, Buyse M (2008) The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials. J Stat Plan Inference 138: 432–449 Nelson RG (1999) An introduction to Copulas. Lecture Notes in Statistics, vol 139. Springer, New York Nyquist H (1924) Certain factors affecting telegraph speed. Bell Syst Tech J 3: 324–346 O’Quigley J (2008) Proportional hazards regression. Springer, New York O’Quigley J, Flandre P (2006) Quantification of the Prentice criteria for surrogate endpoints. Biometrics 64: 297–300 O’Quigley J, Xu R, Stare J (2005) Explained randomness in proportional hazards models. Stat Med 24: 479–489 Prentice RL (1989) Surrogate endpoints in clinical trials: definitions and operational criteria. Stat Med 8: 431–440 Pryseley A, Tilahun A, Alonso A, Molenberghs G (2007) Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints. Clin Trials 4: 587–597 Renard D, Geys H, Molenberghs G, Burzykowski T, Buyse M (2002) Validation of surrogate endpoints in randomized trials with discrete outcomes. Biom J 30: 1–15 Renard D, Geys H, Molenberghs G, Burzykowski T, Buyse M, Vangeneugden T, Bijnens L (2003) Validation of a longitudinally measured surrogate marker for a time-to-event endpoint. Appl Stat 30: 235–247 Sargent DJ, Wieand HJ, Haller DG, Gray R (2003) Disease-free survival versus overall survival as a primary endpoint for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trails. J Clin Oncol 23: 8664–8670 Schemper M, Stare J (1996) Explained variation in survival analysis. Stat Med 15: 1999–2012 Shannon C (1948) A mathematical theory of communication. Bell Syst Tech J 27:379–423 and 623–656 Szilárd L (1929) On the decrease in entropy in a thermodynamic system by the intervention of intelligent beings. Z Phys 53: 840–856 Tibaldi FS, Cortiñas Abrahantes J, Molenberghs G, Renard D, Burzykowski T, Buyse M, Parmar M, Stijnen T, Wolfinger R (2003) Simplified hierarchical linear models for the evaluation of surrogate endpoints. J Stat Comput Simul 73: 643–658 Tilahun A, Assam P, Alonso A, Molenberghs G (2007) Flexible surrogate marker evaluation from several randomized clinical trials with continuous endpoints, using R and SAS. Comput Stat Data Anal 51: 4152–4163 Xu R, O’Quigley J (1999) A measure of dependence for proportional hazards models. J Nonparametr Stat 12: 83–107 Xu R, O’Quigley J (2000) Proportional hazards estimate of the conditional survival function. J R Stat Soc B 62: 667–680